Tryp Therapeutics has submitted an application to uplist to the OTCQB Venture Market. Jim Kuo, CEO of the Company commented, “We are pleased to have initiated the listing process of our common shares on the OTCQB. This move allows Tryp to access a broader range of institutional and retail investors in the U.S. as we develop our drug candidates to treat fibromyalgia and eating disorders.


Previous articlePsyBio Therapeutics Announces Retention of Market Maker
Next articleNoetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector